Macroview Investment Management’s Heron Therapeutics HRTX Stock Holding History

Macroview Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-187	Closed	-$2K	–	346
2020 Q1	$2K	Buy	187 +163	+679%	+$3.06K	﹤0.01%	230
2019 Q4	$1K	Hold	24	–	–	﹤0.01%	289
2019 Q3	$0	Hold	24	–	–	﹤0.01%	306
2019 Q2	$0	Hold	24	–	–	﹤0.01%	330
2019 Q1	$1K	Hold	24	–	–	﹤0.01%	318
2018 Q4	$1K	Sell	24 -111	-82%	-$3.05K	﹤0.01%	305
2018 Q3	$4K	Buy	135 +111	+463%	+$4.13K	0.01%	179
2018 Q2	$1K	Buy	+24	New	+$764	﹤0.01%	265

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macroview Investment Management's HRTX Position: Q2 2020 in Review

Macroview Investment Management sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 187 shares — an estimated $2K sold.

Macroview Investment Management first reported a position in HRTX in Q2 2018 and held it in 8 quarters. The position peaked at $4K in Q3 2018. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

Macroview Investment Management reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
Macroview Investment Management sold 187 Heron Therapeutics shares in Q2 2020, an estimated $2K.
Macroview Investment Management first reported a position in Heron Therapeutics in Q2 2018 and held it in 8 quarters.
Macroview Investment Management's Heron Therapeutics position peaked at $4K in Q3 2018.
190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on Macroview Investment Management's 13F filing for Q2 2020, filed 11 Aug 2020.